(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1133-1141

  Patel, Manish ^a,b   Thomson, Neil C ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WISHAW GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

(R) salbutamol; (S) salbutamol; asthma; b2 agonist; chronic obstructive pulmonary disease (COPD); levosalbutamol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ; INTERLEUKIN 6; IPRATROPIUM BROMIDE; LEUKOTRIENE C4; LEVALBUTEROL; PLACEBO; SALBUTAMOL; STEROID;

AGE DISTRIBUTION; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS MUSCLE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GOBLET CELL; HUMAN; HYPOKALEMIA; ISOMER; LOW DRUG DOSE; LUNG FUNCTION; METERED DOSE INHALER; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PEAK EXPIRATORY FLOW; PREVALENCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TREATMENT RESPONSE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY SYSTEM; STEREOISOMERISM;

EID: 79953893774     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571210     Document Type: Article

References (52)

1. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971;14:995-6
2. Penn RB, Frielle T, McCullough JR, et al. Comparison of R-, S-, and RS-albuterol interaction with human beta 1-and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45 (Pubitemid 126442501)
3. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999;104(2):S31-41 (Pubitemid 29426707)
4. Maier G, Rubino C, Hsu R, et al. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Pulm Pharmacol Ther 2007;20(5):534-42 (Pubitemid 47077644)
5. Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999;12(6):353-62 (Pubitemid 30015807)
6. Dhand R, Goode M, Reid R, et al. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136-41 (Pubitemid 29487451)
7. Ward JK, Dow J, Dallow N, et al. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000;49(1):15-22 (Pubitemid 30050482)
8. Hoiting BH, Meurs H, Schuiling M, et al. Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms. Br J Pharmacol 1996;117:419-26
9. Mitra S, Ugur M, Ugur O, et al. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998;53:347-54 (Pubitemid 28162854)
10. Delmotte P, Sanderson MJ. Effects of formoterol on contraction and Ca2+ signaling of mouse airway smooth muscle cells. Am J Respir Cell Mol Biol 2010;42(3):373-81
11. Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999;104(2):S10-17
12. Volcheck GW, Kelkar P, Bartemes KR, et al. Effects of (R)-and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005;35(10):1341-6
13. Leff AR, Herrnreiter A, Naclerio RM, et al. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997;10(2):97-104 (Pubitemid 29094851)
14. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)-and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109(3):449-54 (Pubitemid 34234195)
15. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005;116(1):65-72 (Pubitemid 40909750)
16. Chorley BN, Li Y, Fang S, et al. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol 2006;34(1):119-27 (Pubitemid 43042864)
17. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001;124(4):478-84 (Pubitemid 32429691)
18. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113(3):503-10 (Pubitemid 38338957)
19. Ibe BO, Abdallah MF, Raj JU. Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008;146(4):321-33 (Pubitemid 351957407)
20. Matera MG, Calzetta L, Rogliani P, et al. Evaluation of the effects of the R-and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol Ther 2011;24(2):221-6
21. Templeton AG, Chapman ID, Chilvers ER, et al. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11(1):1-6 (Pubitemid 28510713)
22. Henderson WR Jr, Banerjee ER, Chi EY. Differential effects of (S)-and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immunol 2005;16:332-40 (Pubitemid 41096540)
23. Auais A, Wedde-Beer K, Piedimonte G. Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatr Pulmonol 2005;40:228-34 (Pubitemid 41254495)
24. Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J Allergy Clin Immunol 2002;110(3):388-94
25. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994;7:367-76
26. Perrin-Fayolle M, Blum PS, Morley J, et al. Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996;14:139-47 (Pubitemid 126442508)
27. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997;52:845-8 (Pubitemid 27473924)
28. Ramsay CM, Cowan J, Flannery E, et al. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999;55:353-9 (Pubitemid 29344078)
29. Lotvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108(5):726-31 (Pubitemid 33096202)
30. Sjosward KN, Hmani M, Davidsson A, et al. Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med 2004;98:990-9 (Pubitemid 40036592)
31. Pleskow WW, Nelson HS, Schaefer K, et al. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429-36 (Pubitemid 40221591)
32. Nowak RM, Emerman CL, Schaefer K, et al. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22(1):29-36 (Pubitemid 38146307)
33. Nowak R, Emerman C, Hanrahan JP, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24:259-67 (Pubitemid 44316800)
34. Thompson M, Wise S, Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. J Emerg Med 2004;26(3):271-7 (Pubitemid 38340824)
35. Jantikar A, Brashier B, Maganji M, et al. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study. Respir Med 2007;101(4):845-9
36. Hamilos DL, D'Urzo A, Levy RJ, et al. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol 2007;99:540-8 (Pubitemid 350308754)
37. Tripp K, McVicar WK, Nair P, et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. J Allergy Clin Immunol 2008;122(3):544-9
38. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143(6):731-6 (Pubitemid 37510640)
39. Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103(4):615-21 (Pubitemid 29295567)
40. Skoner DP, Greos LS, Kim KT, et al. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477-86 (Pubitemid 41720703)
41. Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108(6):938-45 (Pubitemid 33151546)
42. Punj A, Prakash A, Bhasin A. Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma. Indian J Pediatr 2009;76:1131-5
43. Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005;21(7):415-19 (Pubitemid 41061549)
44. Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46(1):29-36 (Pubitemid 40916893)
45. Ralston ME, Euwema MS, Knecht KR, et al. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005;29(1):29-35 (Pubitemid 40800235)
46. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128-35 (Pubitemid 36126724)
47. Donohue JF, Parsey MV, Andrews C, et al. Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD 2006;3:125-32 (Pubitemid 44196022)
48. Freiler JF, Arora R, Kelley TC, et al. Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing. Int J Chron Obstruct Pulmon Dis 2006;1:461-6
49. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110(Suppl. 6):S322-8
50. Schmekel B, Rydberg I, Norlander B, et al. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999;13:1230-5 (Pubitemid 29357136)
51. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993;148:75-9 (Pubitemid 23187221)
52. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6 (Pubitemid 30616699)